Aull & Monroe Investment Management Corp Sells 3,533 Shares of Abbott Laboratories $ABT

Key Points

• Aull & Monroe Investment Management Corp sold 3,533 shares of Abbott Laboratories, reducing its stake by 25.1% to a total of 10,540 shares valued at approximately $1.43 million.
• Analysts have given Abbott Laboratories a consensus rating of Moderate Buy with an average target price of $147.61, with two analysts rating it as a Strong Buy.
• Abbott Laboratories declared a quarterly dividend of $0.59 per share, scheduled for payment on November 17th, reflecting an annualized dividend yield of 1.8%.

Aull & Monroe Investment Management Corp decreased its stake in Abbott Laboratories (NYSE:ABT - Free Report) by 25.1% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 10,540 shares of the healthcare product maker's stock after selling 3,533 shares during the period. Aull & Monroe Investment Management Corp's holdings in Abbott Laboratories were worth $1,434,000 at the end of the most recent quarter.

Several other hedge funds have also bought and sold shares of ABT. Hughes Financial Services LLC acquired a new stake in Abbott Laboratories in the 1st quarter valued at about $27,000. Abound Financial LLC acquired a new stake in shares of Abbott Laboratories in the first quarter valued at approximately $28,000. Elequin Capital LP acquired a new stake in shares of Abbott Laboratories in the first quarter valued at approximately $30,000. JCIC Asset Management Inc. bought a new position in Abbott Laboratories in the first quarter valued at approximately $32,000. Finally, Vision Financial Markets LLC bought a new position in Abbott Laboratories in the first quarter valued at approximately $33,000. 75.18% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the stock. The Goldman Sachs Group lifted their price objective on shares of Abbott Laboratories from $153.00 to $157.00 and gave the company a "buy" rating in a research note on Wednesday, October 1st. Mizuho boosted their price objective on shares of Abbott Laboratories from $135.00 to $140.00 and gave the stock a "neutral" rating in a research note on Tuesday, October 14th. William Blair raised shares of Abbott Laboratories to a "strong-buy" rating in a research report on Thursday, July 17th. Benchmark began coverage on shares of Abbott Laboratories in a research report on Friday, October 10th. They set a "buy" rating and a $145.00 price target on the stock. Finally, Morgan Stanley upped their price objective on shares of Abbott Laboratories from $127.00 to $137.00 and gave the company an "equal weight" rating in a report on Tuesday, July 15th. Two research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and four have given a Hold rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $147.61.

Insider Buying and Selling

In related news, CFO Philip P. Boudreau sold 5,550 shares of the firm's stock in a transaction that occurred on Friday, August 8th. The shares were sold at an average price of $134.55, for a total value of $746,752.50. Following the completion of the transaction, the chief financial officer directly owned 51,003 shares of the company's stock, valued at approximately $6,862,453.65. This trade represents a 9.81% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 0.46% of the company's stock.

Abbott Laboratories Trading Up 0.8%

NYSE:ABT opened at $128.69 on Friday. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.30 and a current ratio of 1.82. The firm has a market cap of $223.98 billion, a price-to-earnings ratio of 16.13, a price-to-earnings-growth ratio of 2.44 and a beta of 0.69. Abbott Laboratories has a 52 week low of $110.86 and a 52 week high of $141.23. The firm has a 50-day moving average price of $132.38 and a two-hundred day moving average price of $131.54.

Abbott Laboratories (NYSE:ABT - Get Free Report) last issued its quarterly earnings results on Wednesday, October 15th. The healthcare product maker reported $1.30 earnings per share (EPS) for the quarter, hitting the consensus estimate of $1.30. Abbott Laboratories had a net margin of 31.88% and a return on equity of 17.78%. The company had revenue of $11.37 billion during the quarter, compared to analyst estimates of $11.40 billion. During the same quarter last year, the business posted $1.21 EPS. Abbott Laboratories's quarterly revenue was up 6.9% compared to the same quarter last year. Abbott Laboratories has set its FY 2025 guidance at 5.120-5.180 EPS. On average, equities analysts expect that Abbott Laboratories will post 5.14 earnings per share for the current fiscal year.

Abbott Laboratories Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, November 17th. Stockholders of record on Wednesday, October 15th will be paid a dividend of $0.59 per share. The ex-dividend date is Wednesday, October 15th. This represents a $2.36 annualized dividend and a dividend yield of 1.8%. Abbott Laboratories's dividend payout ratio (DPR) is presently 29.57%.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.